By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioTime today said that it has reached an agreement with the California Institute for Regenerative Medicine to make five clinical-grade human embryonic stem cell lines available to California researchers.

Under terms of the agreement, BioTime will first provide research-grade cell lines. The Alameda, Calif.-based firm also plans within one year to provide GMP-grade cell lines along with certain documentation and complete DNA sequence information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.